Maria Ostrovsky - 03 Nov 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
05 Nov 2026, 16:24:33 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Charles Schoch, as Attorney-In-Fact for Maria Ostrovsky
Filing notes and source

Key filing fact

Maria Ostrovsky filed Form 4 for Candel Therapeutics, Inc. (CADL) on 05 Nov 2026.

Key facts

  • This page summarizes Maria Ostrovsky's Form 4 filing for Candel Therapeutics, Inc. (CADL).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 05 Nov 2026, 16:24.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002160227 Primary reporting owner

Ostrovsky Maria

Relationship
General Counsel
Address
C/O CANDEL THERAPEUTICS, INC, 117 KENDRICK STREET, SUITE 450, NEEDHAM
Signature
/s/ Charles Schoch, as Attorney-In-Fact for Maria Ostrovsky
Signature date
05 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+315,000
Change %
Price
$0.000000*
Shares after
315,000
Date
03 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
315,000
Exercise price
$8.82
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying this option shall vest and become exercisable on November 3, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .